PETMED EXPRESS INC PETS

Consumer discretionary SIC 5912 - Retail-Drug Stores and Proprietary Stores Nasdaq

PetMed Express, Inc. and subsidiaries, d/b/a PetMeds®, and as parent company of PetCareRx®, is a pioneer in pet healthcare, building a consumer-first digital platform in 1996 that transformed the way customers fulfill pet medications. Thirty years later, as a leading nationwide direct-to-consumer pet health and wellness retailer, the Company markets and sells directly to consumers through its websites (Petmeds.com and PetCareRx.com), customer contact centers, and mobile applications (iOS and Android). The Company provides access to top branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter (OTC) health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and personalized AutoShip capabilities. Our digital platform offers pet healthcare solutions for a broad range of chronic conditions, including those related to allergies, arthritis, anxiety, kidneys, hyperthyroidism, and others for cats, dogs, and horses. We also offer access to a range of non-prescription health and wellness products and Rx food, non-Rx food, and treats. PetMeds and PetCareRx receive the pet's order through our websites and mobile applications and connect to the customer's licensed veterinarian for prescription approval. Through our content website, pethealthmd.com, consumers can access educational articles for any health-related questions regarding their pets. The Company offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service. For 30 years, PetMeds has been a trusted partner in pet health, delivering expert-backed products and pharmacy care to families.

Last close 1.81 2026-09-04
Market cap $39.2M 2026-06-30 share count
52-week range 1.57 - 4.10

Valuation FY2025 figures against the last close

P/S0.2x
P/E
P/FCF
EV/EBITDA
Dividend yield0.1%
Diluted EPS-2.74

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $179.0M$227.0M$274.1M$247.6M$272.3M$303.6M$284.1M$283.4M$273.8M$249.2M
Cost of revenue $157.8M$189.3M$171.1M$195.3M$219.3M$202.9M$188.1M$176.0M$169.9M
Gross profit $50.2M$69.1M$84.8M$76.5M$76.9M$84.3M$81.2M$95.3M$97.8M$79.3M
SG&A $50.7M$38.6M$55.2M$41.7M$31.1M$29.7M$25.3M$24.8M$24.3M$22.8M
Total operating expenses $108.9M$70.7M$92.9M$70.5M$52.7M$53.8M$50.3M$49.1M$45.7M$41.8M
Operating income -$58.7M-$1.5M-$8.2M$6.1M$24.3M$30.5M$31.0M$46.2M$52.1M$37.5M
Pre-tax income -$57.4M-$587.0K-$6.3M$7.4M$24.2M$30.9M$33.9M$49.1M$53.8M$37.9M
Income tax $73.0K$5.7M$1.2M$2.3M$5.5M$7.0M$8.0M$11.4M$16.5M$14.1M
Net income -$57.3M-$6.3M-$7.5M$5.1M$18.7M$23.9M$25.9M$37.7M$37.3M$23.8M
EPS, basic -2.74-0.30-0.370.250.931.191.291.841.831.18
EPS, diluted -2.74-0.30-0.370.250.921.191.291.841.821.17
Shares, diluted (wtd. avg.) $20.9M$20.6M$20.4M$20.3M$20.4M$20.1M$20.1M$20.5M$20.4M$20.4M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $21.4M$54.7M$55.3M$104.1M$111.1M$118.7M$103.8M$100.5M$77.9M$58.7M
Receivables $1.9M$2.3M$3.3M$1.7M$1.9M$2.6M$3.8M$2.5M$2.3M$1.8M
Inventory $13.6M$16.2M$28.6M
Total current assets $43.6M$78.9M$93.6M$130.4M$151.0M$161.2M$129.0M$126.4M$105.2M$81.8M
Property, plant and equipment $26.3M$28.9M$26.7M$26.2M$24.5M$25.4M$25.4M$27.1M$28.7M$30.2M
Goodwill $0$26.7M$26.7M$0
Other intangibles $5.5M$8.0M$11.2M$860.0K$860.0K$860.0K$860.0K$860.0K$860.0K$860.0K
Total assets $81.2M$148.7M$169.9M$167.5M$179.7M$187.5M$155.3M$154.4M$134.8M$112.8M
Accounts payable $20.9M$23.6M$37.0M$25.2M$27.5M$39.5M$19.7M$16.3M$15.3M$15.2M
Total current liabilities $52.0M$62.8M$72.2M$57.5M$56.2M$44.9M$24.3M$18.6M$18.1M$18.4M
Total liabilities $52.3M$63.6M$73.2M$57.5M$56.2M$46.2M$25.3M$19.7M$19.1M$19.4M
Retained earnings $9.3M$66.5M$71.6M$91.7M$115.3M$134.1M$126.2M$122.2M$106.3M$86.5M
Total equity $28.9M$85.1M$96.7M$110.0M$123.5M$124.9M$120.3M$134.7M$115.7M$93.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$28.4M$4.7M$4.3M$27.8M$18.5M$40.1M$38.8M$45.1M$37.4M$47.2M
Depreciation and amortisation $9.4M$7.0M$7.1M$3.5M$2.7M$2.4M$2.3M$2.2M$2.1M$1.4M
Stock-based compensation $1.4M-$6.6M$6.9M$6.6M$4.5M$3.3M$2.8M$3.1M$2.6M$1.9M
Capital expenditure $4.6M$5.1M$4.5M$5.3M$1.8M$2.4M$2.3M$620.0K$703.0K$10.6M
Investing cash flow -$4.6M-$5.1M-$40.7M-$10.3M-$1.8M-$2.4M-$2.3M-$620.0K-$703.0K-$10.6M
Financing cash flow -$299.0K-$181.0K-$12.4M-$24.5M-$24.4M-$22.7M-$33.3M-$21.9M-$17.5M-$15.5M
Dividends paid $21.0K$181.0K$12.4M$24.5M$24.4M$22.7M$21.8M$21.9M$17.5M$15.5M
Buybacks $0$0$11.5M$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001040130-26-000023.

Others in SIC 5912

TickerCompanyMarket capP/ERevenue growth
CVS CVS HEALTH Corp $123.73B 69.6x 7.8%
YI 111, Inc. -9.0%
GRDN Guardian Pharmacy Services, Inc. 17.9%
RDGT Ridgetech Inc. 10.2%